|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||
| Current assets: | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Short-term investments | |||||||||||||
| Contracts receivable | |||||||||||||
| Accounts receivable | |||||||||||||
| Receivable from Ionis Pharmaceuticals, Inc. | |||||||||||||
| Inventories | |||||||||||||
| Other current assets | |||||||||||||
| Total current assets | |||||||||||||
| Property, plant and equipment, net | |||||||||||||
| Licenses, net | |||||||||||||
| Operating lease right-of-use assets | |||||||||||||
| Intangible assets, net | |||||||||||||
| Deposits and other assets | |||||||||||||
| Total assets | |||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||
| Current liabilities: | |||||||||||||
| Accounts payable | |||||||||||||
| Payable to Ionis Pharmaceuticals, Inc. | |||||||||||||
| Accrued compensation | |||||||||||||
| Accrued liabilities | |||||||||||||
| Current portion of deferred revenue | |||||||||||||
| Deferred revenue | |||||||||||||
| Other current liabilities | |||||||||||||
| Total current liabilities | |||||||||||||
| Long-term portion of deferred rent | |||||||||||||
| Long-term portion of lease liabilities | |||||||||||||
| Long-term portion of deferred revenue | |||||||||||||
| Other long-term liabilities | |||||||||||||
| Total liabilities | |||||||||||||
| Stockholders’ equity: | |||||||||||||
| Series A convertible preferred stock, $0.001 par value; no and 28,884,540 shares authorized, no and 28,884,540 shares issued and outstanding at December 31, 2017 and 2016, respectively; aggregate liquidation value of $0 and $610,304 as of December 31, 2017 and 2016, respectively | |||||||||||||
| Common stock, $0.001 par value; 125,000,000 shares authorized at June 30, 2020 and December 31, 2019; 101,509,223 and 100,993,173 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively. | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Accumulated other comprehensive income | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total stockholders’ equity | |||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||
Loading...
